CL2015000416A1 - Compuestos derivados de diazepinona; composicion y combinacion farmaceutica que los comprende, util para el tratamiento de un trastorno o enfermedad mediada por mglur5 tal como sindrome x fragil, enfermedad de parkinson o enfermedad de reflujo. - Google Patents

Compuestos derivados de diazepinona; composicion y combinacion farmaceutica que los comprende, util para el tratamiento de un trastorno o enfermedad mediada por mglur5 tal como sindrome x fragil, enfermedad de parkinson o enfermedad de reflujo.

Info

Publication number
CL2015000416A1
CL2015000416A1 CL2015000416A CL2015000416A CL2015000416A1 CL 2015000416 A1 CL2015000416 A1 CL 2015000416A1 CL 2015000416 A CL2015000416 A CL 2015000416A CL 2015000416 A CL2015000416 A CL 2015000416A CL 2015000416 A1 CL2015000416 A1 CL 2015000416A1
Authority
CL
Chile
Prior art keywords
disease
diazepinone
mglur5
parkinson
disorder
Prior art date
Application number
CL2015000416A
Other languages
English (en)
Inventor
Dirk Behnke
David Carcache
Peter Ertl
Manuel Koller
David Orain
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47045285&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2015000416(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of CL2015000416A1 publication Critical patent/CL2015000416A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D519/00Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CL2015000416A 2012-08-23 2015-02-20 Compuestos derivados de diazepinona; composicion y combinacion farmaceutica que los comprende, util para el tratamiento de un trastorno o enfermedad mediada por mglur5 tal como sindrome x fragil, enfermedad de parkinson o enfermedad de reflujo. CL2015000416A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1215033.0A GB201215033D0 (en) 2012-08-23 2012-08-23 Diazepinone derivatives

Publications (1)

Publication Number Publication Date
CL2015000416A1 true CL2015000416A1 (es) 2015-04-24

Family

ID=47045285

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2015000416A CL2015000416A1 (es) 2012-08-23 2015-02-20 Compuestos derivados de diazepinona; composicion y combinacion farmaceutica que los comprende, util para el tratamiento de un trastorno o enfermedad mediada por mglur5 tal como sindrome x fragil, enfermedad de parkinson o enfermedad de reflujo.

Country Status (44)

Country Link
US (4) US8853203B2 (es)
EP (1) EP2888259B1 (es)
JP (2) JP6169699B2 (es)
KR (1) KR102104149B1 (es)
CN (1) CN104520298B (es)
AP (1) AP2014008140A0 (es)
AR (1) AR092212A1 (es)
AU (1) AU2013307239B2 (es)
BR (1) BR112015003281A8 (es)
CA (1) CA2878564C (es)
CL (1) CL2015000416A1 (es)
CR (1) CR20150092A (es)
CU (1) CU20150016A7 (es)
CY (1) CY1120728T1 (es)
DK (1) DK2888259T3 (es)
EA (1) EA029493B1 (es)
ES (1) ES2672737T3 (es)
GB (1) GB201215033D0 (es)
GT (1) GT201500039A (es)
HK (1) HK1206008A1 (es)
HR (1) HRP20180850T1 (es)
HU (1) HUE037971T2 (es)
IL (1) IL237062A (es)
JO (1) JOP20130250B1 (es)
LT (1) LT2888259T (es)
MA (1) MA37849A1 (es)
MX (1) MX365253B (es)
MY (1) MY170103A (es)
NO (1) NO2888259T3 (es)
NZ (1) NZ703628A (es)
PE (1) PE20150401A1 (es)
PH (1) PH12015500373B1 (es)
PL (1) PL2888259T3 (es)
PT (1) PT2888259T (es)
RS (1) RS57231B1 (es)
SG (2) SG11201500068QA (es)
SI (1) SI2888259T1 (es)
TN (1) TN2014000528A1 (es)
TR (1) TR201807174T4 (es)
TW (1) TWI616444B (es)
UA (1) UA114326C2 (es)
UY (1) UY34986A (es)
WO (1) WO2014030128A1 (es)
ZA (1) ZA201409345B (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201215033D0 (en) * 2012-08-23 2012-10-10 Novartis Ag Diazepinone derivatives
US11878001B2 (en) 2017-07-31 2024-01-23 Novartis Ag Use of mavoglurant in the reduction of ***e use or in preventing relapse into ***e use
JP2022518788A (ja) * 2019-01-29 2022-03-16 ノバルティス アーゲー オピオイド鎮痛耐性を治療するためのmGluR5アンタゴニストの使用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3853851A (en) * 1972-01-26 1974-12-10 Ciba Geigy Corp Diazepinoisoquinolines
GB0128996D0 (en) 2001-12-04 2002-01-23 Novartis Ag Organic compounds
CN100457731C (zh) * 2003-03-26 2009-02-04 麦克公司 代谢型谷氨酸受体的苯甲酰胺调节剂
GB0413605D0 (en) * 2004-06-17 2004-07-21 Addex Pharmaceuticals Sa Novel compounds
TW200811157A (en) * 2006-05-05 2008-03-01 Astrazeneca Ab mGluR5 modulators I
CU20090172A6 (es) 2009-10-09 2011-10-05 Facultad De Quimica Universidad De La Habana Sistemas tricíclicos y tetracíclicos con actividad sobre el sistema nervioso central y vascular
US8772301B2 (en) * 2009-12-18 2014-07-08 Sunovion Pharmaceuticals, Inc. Compounds for treating disorders mediated by metabotropic glutamate receptor 5, and methods of use thereof
US9453021B2 (en) 2011-05-10 2016-09-27 Kyowa Hakko Kirin Co., Ltd. Pyrimidodiazepinone compound
GB201215033D0 (en) * 2012-08-23 2012-10-10 Novartis Ag Diazepinone derivatives

Also Published As

Publication number Publication date
GT201500039A (es) 2018-11-27
PT2888259T (pt) 2018-06-06
KR102104149B1 (ko) 2020-04-24
CY1120728T1 (el) 2019-12-11
SG10201701333WA (en) 2017-04-27
US20170305903A1 (en) 2017-10-26
PH12015500373A1 (en) 2015-04-20
NZ703628A (en) 2018-05-25
AR092212A1 (es) 2015-04-08
CA2878564A1 (en) 2014-02-27
US20140357625A1 (en) 2014-12-04
US20140057902A1 (en) 2014-02-27
MX365253B (es) 2019-05-28
TW201412736A (zh) 2014-04-01
SG11201500068QA (en) 2015-05-28
JOP20130250B1 (ar) 2021-08-17
ZA201409345B (en) 2015-12-23
PL2888259T3 (pl) 2018-08-31
CR20150092A (es) 2015-05-04
MY170103A (en) 2019-07-05
AU2013307239A1 (en) 2015-01-29
CN104520298B (zh) 2016-10-19
PE20150401A1 (es) 2015-04-16
JP6169699B2 (ja) 2017-07-26
TWI616444B (zh) 2018-03-01
US9650377B2 (en) 2017-05-16
AU2013307239B2 (en) 2015-12-24
EP2888259A1 (en) 2015-07-01
US9284331B2 (en) 2016-03-15
SI2888259T1 (en) 2018-07-31
KR20150044897A (ko) 2015-04-27
US8853203B2 (en) 2014-10-07
MX2015002367A (es) 2015-06-03
EA201590415A1 (ru) 2015-06-30
LT2888259T (lt) 2018-06-11
MA37849A1 (fr) 2017-09-29
BR112015003281A2 (pt) 2017-07-04
UA114326C2 (uk) 2017-05-25
DK2888259T3 (en) 2018-06-14
CU20150016A7 (es) 2015-07-30
EP2888259B1 (en) 2018-03-07
CN104520298A (zh) 2015-04-15
ES2672737T3 (es) 2018-06-15
NO2888259T3 (es) 2018-08-04
JP2017226661A (ja) 2017-12-28
TN2014000528A1 (en) 2016-03-30
TR201807174T4 (tr) 2018-06-21
HK1206008A1 (en) 2015-12-31
UY34986A (es) 2014-03-31
WO2014030128A1 (en) 2014-02-27
HRP20180850T1 (hr) 2018-06-29
EA029493B1 (ru) 2018-04-30
PH12015500373B1 (en) 2015-04-20
HUE037971T2 (hu) 2018-10-29
US20160159795A1 (en) 2016-06-09
AP2014008140A0 (en) 2014-12-31
IL237062A (en) 2016-11-30
GB201215033D0 (en) 2012-10-10
CA2878564C (en) 2021-08-03
BR112015003281A8 (pt) 2018-01-16
RS57231B1 (sr) 2018-07-31
JP2015526461A (ja) 2015-09-10

Similar Documents

Publication Publication Date Title
CL2014002919A1 (es) Compuestos derivados de 1h-indol-4-il-metil-(heterociclo benzofusionado); composicion y combinacion farmaceutica; y uso en el tratamiento de un trastorno mediado por la activacion del complemento o la ruta alternativa del mismo.
CO7071129A2 (es) Esketamina para el tratamiento de la depresión refractaria al tratamiento o resistente al tratamiento
CL2015000487A1 (es) Compuestos derivados de sulfamoilarilamidas; composicion farmaceutica que los comprende, util para la prevencion o tratamiento de una infeccion por el virus de la hepatitis b (vhb).
CL2015000295A1 (es) Compuestos derivados de alquilpirimidina; composicion farmaceutica que los comprende; uso para el tratamiento de infecciones víricas y otras enfermedades.
CL2015001265A1 (es) Compuestos derivados de 2-aminoquinazolina sustituidos; composicion farmaceutica que los comprende, util para el tratamiento de un trastorno en el que interviene la modulacion de tlr7 y/o tlr8 tal como infecciones viricas.
CL2014002873A1 (es) Compuestos derivados de pirimidin-amina o triazin-amina, inhibidores de adn-pk; composicion farmaceutica; y su uso para el tratamiento del cancer.
CL2014001065A1 (es) Compuestos derivados de piridopirazinas; composicion farmaceutica que los comprende; y su uso para la prevencion o el tratamiento de un estado patologico o afeccion mediada por una fgfr cinasa tal como cancer.
CL2013001964A1 (es) Compuestos derivados de heterociclos, como inhibidores de bace 1 o 2; composicion farmaceutica que los comprende; combinacion farmaceutica; y su uso para el tratamiento o prevencion de la enfermedad de alzheimer o deterioro cognitivo leve, resistencia a la insulina, diabetes tipo 2, entre otras.
BR112015001596A2 (pt) composição para o tratamento de hiperlipidemia que compreende oxintomodulina.
CL2015001733A1 (es) Compuestos derivados de lactamas fusionadas de arilo y heteroarilo, moduladores de ezh2; composicion farmaceutica que los comprende; uso del compuesto para el tratamiento del cancer.
CL2014003388A1 (es) Compuestos derivados de triazolona, como inhibidores de mpges-1; proceso de preparacion de dichos compuestos; composicion farmaceutica que los comprende, util para el tratamiento de inflamacion, asma, epoc, artritis, enfermedad de parkinson y enfermedades autoinmunes, entre otras enfermedades.
CL2015000711A1 (es) Compuestos derivados de bis(fluoroalquil)-1,4-benzodiazepinona como inhibidores de notch; composicion farmaceutica y uso en el tratamiento del cancer.
CL2014002257A1 (es) Compuestos derivados de 6-alquinilo piridinas, como mimeticos smac; composicion farmaceutica que los comprende; y su uso para el tratamiento y/o prevencion del cancer.
CL2014002093A1 (es) Compuestos derivados piperidinopirimidinicos; composicion farmaceutica que los comprende; uso en el tratamiento de infecciones viricas.
EP3501527C0 (en) COMPOSITION FOR PREVENTING OR TREATING A MENTAL DISORDER, CONTAINING A VESICLE DERIVED FROM BACTERIA OF AN ELACTOBACILLUS SPECIES
ES2694290T5 (es) Composiciones farmacéuticas para el tratamiento de enfermedades mediadas por CFTR
CL2015001279A1 (es) Compuestos derivados de piridina, inhibidores del transportador de uratos urat 1; composicion farmaceutica que los comprende; uso para el tratamiento o prevencion de enfermedades tales como gota, hiperuricemia, hipertensión, enfermedades renales, entre otras.
ECSP16078782A (es) Compuestos de isoindolinona como moduladores de gpr119 para el tratamiento de diabetes, obesidad, dislipidemia y trastornos relacionados
BR112014030071A2 (pt) processo para a fabricação de um vapor de dafd, e, composição
DK2968218T3 (da) Kombination til behandling af parkinsons sygdom
CL2014002756A1 (es) Compuestos derivados de 1,4-benzotiazepina; composición farmacéutica que lo comprende; uso para tratar afecciones relacionadas con función anormal de receptores de rianodina; y método de preparación del compuesto.
CL2015000615A1 (es) Compuestos derivados de 4-amino-quinolinas, inhibidores de rip2 cinasa; composicion farmaceutica que los comprende; uso para el tratamiento de enfermedades tales como enfermedad de crohn, colitis ulcerativa o sindrome de blau.
CL2014003429A1 (es) Compuestos especificos derivados de indanosulfamida; composicion farmaceutica que los comprende, utiles en el tratamiento e la epilepsia.
WO2013138568A8 (en) Liver x receptor modulators
BR112014028622A2 (pt) composições de ativador de glucoquinase para o tratamento de diabetes